Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT06793371 · Cytokinetics

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

(AMBER-HFpEF)

What this study is about

This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.

View original scientific description

This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.

Interventions

DRUG

CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)

CK-4021586 administered orally

DRUG

Placebo to match CK-4021586

Placebo administered orally

Primary outcome measures

Incidence of early drug discontinuation

Time frame: 12 weeks

Incidence of early drug discontinuation observed during dosing of CK 4021586 in patients with HFpEF

Incidence of LVEF < 40%

Time frame: 12 weeks

Incidence of left-ventricular ejection fraction (LVEF) \< 40% observed during dosing of CK-4021586 in patients with HFpEF

Incidence of AEs

Time frame: 12 weeks

Incidence of adverse events observed during dosing of CK-4021586 in patients with HFpEF

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • Males and females ≥ 40 years and ≤ 85 years of age at screening.
  • Diagnosed with HF with NYHA functional class II or III.
  • Screening echocardiography with LVEF ≥ 60%.
  • Screening NT-proBNP ≥ 300 pg/mL for participants in sinus rhythm and ≥ 900 pg/mL for participants with comorbid atrial fibrillation or flutter.
  • Body mass index \< 40 kg/m2.
  • Participants on beta-blockers, angiotensin-converting enzyme (ACE)/angiotensin II receptor blocker (ARB) or angiotensin receptor/neprilysin inhibitor (ARNI), or sodium-glucose contransporter-2 (SGLT2)-inhibitors must be on stable doses for more than 4 weeks prior to screening.
  • Participants on a glucagon-like peptide-1 (GLP-1) agonist must be on a stable dose for more than 24 weeks prior to screening with no anticipated plans to change dose during this study.

Exclusion criteria

  • History or evidence of any other clinically significant disorder, malignancy, active infection, other condition, or disease that, in the opi

Where

  • Fairhope, Alabama
  • Tucson, Arizona
  • Little Rock, Arkansas
  • Imperial, California
  • Pasadena, California
  • San Francisco, California
  • Santa Maria, California
  • Vista, California
  • Hialeah, Florida
  • Weston, Florida
  • Peoria, Illinois
  • Slidell, Louisiana

And 12 more locations — see the full list below.

Related conditions & keywords

Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)Symptomatic heart failure with preserved ejection fractionHFpEFHeart failureCK-4021586CK-586AMBER-HFpEFAMBERCardiac myosin inhibitorCMICY 9021ulacamten

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced May 29, 2026 · Source of record for eligibility and locations

📊
1 of 60 participants interested
2% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

RECRUITING

Fairhope

Alabama

Location available
RECRUITING

Tucson

Arizona

Location available
RECRUITING

Little Rock

Arkansas

Location available
RECRUITING

Imperial

California

Location available
RECRUITING

Pasadena

California

Location available
RECRUITING

San Francisco

California

Location available
RECRUITING

Santa Maria

California

Location available
RECRUITING

Vista

California

Location available
View Vista location page
RECRUITING

Hialeah

Florida

Location available

And 16 more locations available.

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Find More Heart Failure Trials by City

Browse all heart failure clinical trials in these cities — not just this study.

Looking for Heart Failure Treatment in Fairhope?

Join others in Alabama exploring innovative treatment options through clinical research

Heart Failure Treatment Options in Fairhope, Alabama

If you're searching for Heart Failure treatment in Fairhope, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Fairhope, Tucson, Little Rock and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Heart Failure. All study-related care is provided at no cost to participants.

Local Sites
3 locations in Alabama
Now Enrolling
Up to 60 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Heart Failure?

Potential Benefits

  • Access to new treatment approaches before public availability
  • Close monitoring by experienced medical professionals
  • Study-related care provided at no cost
  • Contribute to medical research for Heart Failure

What to Expect

  • Initial screening to determine eligibility
  • Regular check-ups and monitoring visits
  • Possible compensation for time and travel
  • You can withdraw at any time

Frequently Asked Questions About This Heart Failure Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06793371. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.